Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0LE2E
|
|||
| Former ID |
DNC000721
|
|||
| Drug Name |
H22xKi-4
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Lymphocyte activation antigen CD30 (TNFRSF8) | Target Info | . | [1] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NetPath Pathway | Leptin Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood. 2002 Nov 1;100(9):3101-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.